Natural history and outcome of light chain deposition disease

Blood

Volumn 126, Issue 26, 2015, Pages 2805-2810

  Sayed, Rabya H ^a   Wechalekar, Ashutosh D ^a   Gilbertson, Janet A ^a   Bass, Paul ^a   Mahmood, Shameem ^a   Sachchithanantham, Sajitha ^a   Fontana, Marianna ^a   Patel, Ketna ^a   Whelan, Carol J ^a   Lachmann, Helen J ^a   Hawkins, Philip N ^a   Gillmore, Julian D ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BORTEZOMIB; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN; STEROID; THALIDOMIDE;

ADULT; AGED; ARTICLE; DIALYSIS; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; KIDNEY DYSFUNCTION; KIDNEY GRAFT; LIGHT CHAIN DEPOSITION DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MORTALITY; PARAPROTEINEMIAS; PATHOLOGY;

FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARAPROTEINEMIAS;

EID: 84954516000     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-07-658872     Document Type: Article

References (26)

1. Randall RE, Williamson WC Jr, Mullinax F, Tung MY, Still WJ. Manifestations of systemic light chain deposition. Am J Med. 1976;60(2):293-299.
2. Nasr SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7(2):231-239.
3. Masai R, Wakui H, Togashi M, et al. Clinicopathological features and prognosis in immunoglobulin light and heavy chain deposition disease. Clin Nephrol. 2009;71(1):9-20.
4. Pozzi C, Locatelli F. Kidney and liver involvement in monoclonal light chain disorders. Semin Nephrol. 2002;22(4):319-330.
5. Batuman V, Guan S. Receptor-mediated endocytosis of immunoglobulin light chains by renal proximal tubule cells. Am J Physiol. 1997; 272(4 Pt 2):F521-F530.
6. Ronco P, Plaisier E, Mougenot B, Aucouturier P. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol. 2006;1(6):1342-1350.
7. Matsuzaki K, Ohsawa I, Nishitani T, et al. Marked improvement by high-dose chemotherapy and autologous stem cell transplantation in a case of light chain deposition disease. J Nephrol. 2011; 24(2):246-249.
8. Pozzi C, Locatelli F. The patient with insidious chronic renal failure and the patient with the nephrotic syndrome-two manifestations of a protean and not so rare disease. Nephrol Dial Transplant. 1996;11(9):1876-1880.
9. Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol. 2001; 12(7):1482-1492.
10. Buxbaum J. Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol Oncol Clin North Am. 1992;6(2):323-346.
11. Pozzi C, Fogazzi GB, Banfi G, Strom EH, Ponticelli C, Locatelli F. Renal disease and patient survival in light chain deposition disease. Clin Nephrol. 1995;43(5):281-287.
12. Leung N, Lager DJ, Gertz MA, Wilson K, Kanakiriya S, Fervenza FC. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis. 2004;43(1):147-153.
13. Short AK, O'Donoghue DJ, Riad HN, Short CD, Roberts IS. Recurrence of light chain nephropathy in a renal allograft. A case report and review of the literature. Am J Nephrol. 2001;21(3):237-240.
14. Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. J Histochem Cytochem. 1962;10:355-364.
15. Tennent GA, Cafferty KD, Pepys MB, Hawkins PN. Congo red overlay immunohistochemistry aids classification of amyloid deposits. In: Kyle RA, Gertz MA, eds. Amyloid and Amyloidosis 1998. Pearl River, NY: Parthenon Publishing; 1999:160-162.
16. Chang A, Peutz-Kootstra CJ, Richardson CA, Alpers CE. Expanding the pathologic spectrum of light chain deposition disease: a rare variant with clinical follow-up of 7 years. Mod Pathol. 2005; 18(7):998-1004.
17. Schwartz MM. Monoclonal immunoglublin deposition diseases. In: Jennete J, Olson JL, Schwartz MM, Silvia FG, eds. Hepinstalls' Pathology of the Kidney. 6th ed. Baltimore: Williams & Wilkins; 2007:869-877.
18. Colombat M, Gounant V, Mal H, Callard P, Milleron B. Light chain deposition disease involving the airways: diagnosis by fibreoptic bronchoscopy. Eur Respir J. 2007;29(5): 1057-1060.
19. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9.
20. Rajkumar SV, Merlini G, San Miguel JF. Haematological cancer: Redefining myeloma. Nat Rev Clin Oncol. 2012;9(9):494-496.
21. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541-4549.
22. Turin TC, James M, Ravani P, et al. Proteinuria and rate of change in kidney function in a community-based population. J Am Soc Nephrol. 2013;24(10):1661-1667.
23. Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest. 1950;29(5): 496-507.
24. Pinney JH, Lachmann HJ, Bansi L, et al. Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol. 2011;29(6):674-681.
25. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99(12):4276-4282.
26. Carlson K, Hjorth M, Knudsen LM; Nordic Myeloma Study Group. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure-a retrospective analysis and recommendations for dose adjustment. Br J Haematol. 2005; 128(5):631-635.